Managers / Q3 2023 · view latest →
BML Capital Management, LLC
CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447
Summary
Bml Capital Management, LLC reported $109M in U.S.-listed holdings across 26 positions for Q3 2023.
The portfolio is heavily concentrated: Ishares Tr alone accounts for 25.0% of reported value.
Compared with Q2 2023, the fund opened 3 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 42.2% · $46M
- Common Stock · 33.1% · $36M
- Other · 24.7% · $27M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VTGNVISTAGEN THERAPEUTICS INC | NEW | +100.0K | 100.0K | +$524,000 | $524,000 |
| NDQINVESCO QQQ TR | NEW | +108 | 108 | +$443,880 | $443,880 |
| NEOLEUKIN THERAPEUTICS INC | NEW | +98.7K | 98.7K | +$389,723 | $389,723 |
| AVROBIO INC | ADDED | +3.75M | 4.00M | +$6M | $6M |
| AVIRATEA PHARMACEUTICALS INC | ADDED | +2.56M | 4.80M | +$6M | $14M |
| PARDES BIOSCIENCES INC | SOLD OUT | −3.79M | 0 | −$7M | $0 |
| ANFABERCROMBIE & FITCH CO | SOLD OUT | −117.5K | 0 | −$4M | $0 |
| QUINCE THERAPEUTICS INC | SOLD OUT | −1.41M | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $156M | 16 | May 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $116M | 16 | Feb 3, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $109M | 20 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $132M | 24 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 27 | May 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $161M | 25 | Feb 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $170M | 29 | Nov 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $140M | 28 | Aug 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $152M | 32 | Apr 24, 2024 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2023 | $132M | 35 | Feb 2, 2024 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2023 | $109M | 26 | Oct 23, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $111M | 31 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $116M | 31 | Apr 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $105M | 25 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.